Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSC's quarterly Ending Cash Position
declined
from Dec. 2025 (₫91,326 Mil) to Mar. 2026 (₫44,163 Mil) but then
increased
from Mar. 2026 (₫44,163 Mil) to Jun. 2026 (₫52,003 Mil).
Viet Nam Pharmaceutical - JSC's annual Ending Cash Position
increased
from Dec. 2023 (₫104,326 Mil) to Dec. 2024 (₫289,066 Mil) but then
declined
from Dec. 2024 (₫289,066 Mil) to Dec. 2025 (₫91,326 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC Ending Cash Position Chart
Viet Nam Pharmaceutical - JSC Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
What does a Ending Cash Position of ₫52,003 Mil mean?
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Ending Cash Position of ₫52,003 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Viet Nam Pharmaceutical - JSC and its competitors.
Is Viet Nam Pharmaceutical - JSC's Ending Cash Position too high?
Viet Nam Pharmaceutical - JSC's current Ending Cash Position is ₫52,003 Mil. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Ending Cash Position compare to ZTS?
Viet Nam Pharmaceutical - JSC's Ending Cash Position of ₫52,003 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. Viet Nam Pharmaceutical - JSC's current Ending Cash Position is ₫52,003 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,203.86, compared to a current price of ₫17,800.00 — trading 19.8% below its estimated fair value. The current Ending Cash Position is ₫52,003 Mil. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Ending Cash Position is ₫52,003 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫17,800.00 is trading 19.8% below its estimated GF Value™ of ₫22,203.86.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
Ending Cash Position: ₫52,003 Mil
GF Value™: ₫22,203.86 vs. price of ₫17,800.00 (19.8% below fair value)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
82GF Score
Get the complete analysis for HSTC:DVN
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
